Literature DB >> 27518544

Licence to save: a UK survey of anti-VEGF use for the eye in 2015.

A K Shalaby1, K Lewis1, K Bush1, P R Meredith1,2, S Di Simplicio1, A J Lockwood1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27518544      PMCID： PMC5108014          DOI： 10.1038/eye.2016.154

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  12 in total

Review 1.  Paediatric prescribing: using unlicensed drugs and medicines outside their licensed indications.

Authors:  J Collier
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  Avastin and Lucentis: a guide through the legal maze.

Authors:  David Lock
Journal:  BMJ       Date:  2015-04-01

Review 3.  Anti-vascular endothelial growth factor for diabetic macular oedema.

Authors:  Gianni Virgili; Mariacristina Parravano; Francesca Menchini; Jennifer R Evans
Journal:  Cochrane Database Syst Rev       Date:  2014-10-24

4.  Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries.

Authors:  Lesley H Curtis; Bradley G Hammill; Laura G Qualls; Lisa D DiMartino; Fang Wang; Kevin A Schulman; Scott W Cousins
Journal:  Am J Ophthalmol       Date:  2012-02-08       Impact factor: 5.258

5.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

Authors:  Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245

6.  Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.

Authors:  Usha Chakravarthy; Simon P Harding; Chris A Rogers; Susan M Downes; Andrew J Lotery; Lucy A Culliford; Barnaby C Reeves
Journal:  Lancet       Date:  2013-07-19       Impact factor: 79.321

7.  Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).

Authors:  Soraya Rofagha; Robert B Bhisitkul; David S Boyer; SriniVas R Sadda; Kang Zhang
Journal:  Ophthalmology       Date:  2013-05-03       Impact factor: 12.079

Review 8.  Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.

Authors:  Lorenzo Moja; Ersilia Lucenteforte; Koren H Kwag; Vittorio Bertele; Annalisa Campomori; Usha Chakravarthy; Roberto D'Amico; Kay Dickersin; Laurent Kodjikian; Kristina Lindsley; Yoon Loke; Maureen Maguire; Daniel F Martin; Alessandro Mugelli; Bernd Mühlbauer; Isabel Püntmann; Barnaby Reeves; Chris Rogers; Christine Schmucker; Manju L Subramanian; Gianni Virgili
Journal:  Cochrane Database Syst Rev       Date:  2014-09-15

9.  Comparing the effectiveness and costs of Bevacizumab to Ranibizumab in patients with Diabetic Macular Edema: a randomized clinical trial (the BRDME study).

Authors:  A M E Schauwvlieghe; G Dijkman; J M Hooymans; F D Verbraak; C B Hoyng; M G W Dijkgraaf; R Van Leeuwen; J R Vingerling; A C Moll; Reinier O Schlingemann
Journal:  BMC Ophthalmol       Date:  2015-07-07       Impact factor: 2.209

10.  Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.

Authors:  Helen A Dakin; Sarah Wordsworth; Chris A Rogers; Giselle Abangma; James Raftery; Simon P Harding; Andrew J Lotery; Susan M Downes; Usha Chakravarthy; Barnaby C Reeves
Journal:  BMJ Open       Date:  2014-07-29       Impact factor: 2.692
View more
  7 in total

1.  Bevacizumab: a new way of doing business. Part 2.

Authors:  Andrew J Lotery; Michael A Burdon
Journal:  Eye (Lond)       Date:  2018-11-27       Impact factor: 3.775

2.  Comment on 'Licence to save: a UK survey of anti-VEGF use for the eye in 2015'.

Authors:  C MacGregor; C Whaley; N Maycock
Journal:  Eye (Lond)       Date:  2017-08-25       Impact factor: 3.775

3.  Off-label use of bevacizumab for wet age-related macular degeneration in Europe.

Authors:  Tomas Bro; Magdalena Derebecka; Øystein Kalsnes Jørstad; Andrzej Grzybowski
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-12-30       Impact factor: 3.117

Review 4.  A systematic review to assess the 'treat-and-extend' dosing regimen for neovascular age-related macular degeneration using ranibizumab.

Authors:  S R Rufai; H Almuhtaseb; R M Paul; B L Stuart; T Kendrick; H Lee; A J Lotery
Journal:  Eye (Lond)       Date:  2017-05-05       Impact factor: 3.775

5.  The disparity between funding for eye research vs. the high cost of sight-loss in the UK.

Authors:  Jennifer M Dewing; Andrew J Lotery; J Arjuna Ratnayaka
Journal:  Eye (Lond)       Date:  2022-09-27       Impact factor: 4.456

6.  Exploring factors predicting changes in patients' expectations and psychosocial issues during the course of treatment with intravitreal injections for wet age-related macular degeneration.

Authors:  S Sii; P Aspinall; S Borooah; B Dhillon
Journal:  Eye (Lond)       Date:  2017-12-08       Impact factor: 3.775

7.  Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems.

Authors:  Robert P Finger; Vincent Daien; Bora M Eldem; James S Talks; Jean-Francois Korobelnik; Paul Mitchell; Taiji Sakamoto; Tien Yin Wong; Krystallia Pantiri; Joao Carrasco
Journal:  BMC Ophthalmol       Date:  2020-07-17       Impact factor: 2.209
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.